Voyager Therapeutics (NASDAQ:VYGR) Issues Earnings Results

Voyager Therapeutics (NASDAQ:VYGR) issued its quarterly earnings data on Monday. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.08, FiscalAI reports. The firm had revenue of $13.46 million during the quarter, compared to the consensus estimate of $10.49 million. Voyager Therapeutics had a negative return on equity of 48.94% and a negative net margin of 404.85%.

Voyager Therapeutics Stock Performance

Shares of NASDAQ:VYGR opened at $4.11 on Tuesday. The company has a market capitalization of $228.52 million, a P/E ratio of -1.90 and a beta of 1.32. The company’s 50-day moving average is $3.85 and its 200 day moving average is $4.14. Voyager Therapeutics has a fifty-two week low of $2.64 and a fifty-two week high of $5.55.

Insider Buying and Selling

In other Voyager Therapeutics news, CEO Alfred Sandrock sold 14,197 shares of Voyager Therapeutics stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $3.79, for a total value of $53,806.63. Following the sale, the chief executive officer owned 484,060 shares of the company’s stock, valued at approximately $1,834,587.40. The trade was a 2.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold a total of 49,783 shares of company stock valued at $188,694 over the last 90 days. Insiders own 4.53% of the company’s stock.

Institutional Trading of Voyager Therapeutics

A number of institutional investors have recently modified their holdings of the business. Opaleye Management Inc. bought a new stake in shares of Voyager Therapeutics during the 4th quarter valued at about $4,704,000. Geode Capital Management LLC lifted its position in Voyager Therapeutics by 1.1% during the second quarter. Geode Capital Management LLC now owns 1,116,847 shares of the company’s stock valued at $3,474,000 after purchasing an additional 11,929 shares during the last quarter. UBS Group AG grew its stake in Voyager Therapeutics by 3.9% in the 3rd quarter. UBS Group AG now owns 473,100 shares of the company’s stock worth $2,209,000 after buying an additional 17,558 shares in the last quarter. Fiduciary Trust Co increased its holdings in shares of Voyager Therapeutics by 28.9% in the 3rd quarter. Fiduciary Trust Co now owns 334,397 shares of the company’s stock worth $1,562,000 after buying an additional 75,000 shares during the last quarter. Finally, Wells Fargo & Company MN increased its holdings in shares of Voyager Therapeutics by 26.7% in the 4th quarter. Wells Fargo & Company MN now owns 132,663 shares of the company’s stock worth $521,000 after buying an additional 27,964 shares during the last quarter. 48.03% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

VYGR has been the topic of several recent analyst reports. Wedbush restated an “outperform” rating and set a $8.00 price objective on shares of Voyager Therapeutics in a research note on Tuesday, November 11th. Wall Street Zen lowered shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 21st. Finally, HC Wainwright dropped their target price on shares of Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating on the stock in a research report on Wednesday, November 12th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $13.75.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.